Not Signed In -
Alemtuzumab |
Campath |
Image:Alemtuzumab.png Alemtuzumab Systematic (IUPAC) name Humanized anti-CD52 antibody Identifiers CAS number ? ATC code ? PubChem ? DrugBank BTD00109 Chemical data Formula C6468H10066N1732O2005S40 Mol. weight 145453.8 g/mol Pharmacokinetic data Bioavailability ? Metabolism ? Half life ~288 hrs Excretion ? Therapeutic considerations Pregnancy cat. ? Legal status Routes ? Alemtuzumab (marketed as Campat ...
Wikipedia - [full article]
Alemtuzumab News Headlines
- Final Data From Phase III Study Show Single-Agent Alemtuzumab (Campath(R), MabCampath(R)) Superior To Chlorambucil For Patients With Untreated B-CLL
MedicalNewsToday - Tue, 12 Dec 2006 08:00 EST
- Data From Phase III Comparative Study Show Campath(R) Superior To Chlorambucil As A First-line Therapy In B-CLL
MedicalNewsToday - Tue, 12 Dec 2006 08:00 EST
- Genzyme Reports Interim Results From Trial Of Campath(R) For Multiple Sclerosis
MedicalNewsToday - Fri, 15 Sep 2006 07:00 EST
- Alemtuzumab effective in poor-genetic-risk chronic lymphocytic leukaemia
MedicalNewsToday - Fri, 17 Jun 2005 09:00 EST
- Chronic Lymphoblastic Leukaemia - Fludarabine with alemtuzumab (FluCam) gives over 80% response rate
MedicalNewsToday - Tue, 07 Jun 2005 10:00 EST
email this page
print this page
bookmark this page
feedback on this page
